Hormone therapy and cardiovascular disease

Area of Science:

• Cardiology
• Endocrinology
• Women's Health

Background:

• Cardiovascular disease (CVD) is the leading cause of death for women in Taiwan, particularly postmenopausal women.
• Menopause-related estrogen deficiency is linked to increased CVD risk, with coronary artery disease and stroke being primary concerns.
• Previous observational studies suggested hormone therapy (HT) reduces coronary artery disease risk.

Purpose of the Study:

• To review the current understanding of cardiovascular disease risk in postmenopausal women.
• To evaluate the efficacy and risks of hormone therapy (HT) for cardiovascular disease (CVD) prevention.
• To emphasize the need for individualized treatment decisions regarding HT in postmenopausal women.

Main Methods:

• Review of observational studies and randomized controlled trials on hormone therapy (HT) and cardiovascular disease (CVD) prevention.
• Analysis of the effects of estrogen and HT on lipid profiles and cardiovascular risk factors.
• Discussion of the multifactorial nature of CVD development and progression.

Main Results:

• Randomized controlled trials have raised questions about the efficacy of HT for primary and secondary CVD prevention, despite its lipid-lowering effects.
• Estrogen deficiency post-menopause is a significant factor in CVD risk for women.
• The complex interplay of various factors in CVD genesis necessitates further research.

Conclusions:

• The role of HT in cardiovascular disease (CVD) prevention for postmenopausal women remains complex and requires further investigation.
• Individualized patient assessment is crucial when considering HT, weighing potential benefits against risks.
• Future research should focus on the efficacy of different HT preparations and dosages in at-risk postmenopausal women before significant atheromatous lesion development.